Figure 5

Preservation of mTORC1 activation and neurotrophic factors induced by Rheb(S16H) in neuroinflammatory conditions. (a) Double-immunofluorescence staining for TH (red) and p-4E-BP1 (green), TH and GDNF (green), and TH and BDNF (green) in the SN at 3 weeks after AAV1-Rheb(S16H) administration. CON, contralateral control side. Scale bars, 20 μm. (b) Western blot analysis of 4E-BP1, p-4E-BP1, GDNF and BDNF in the SN at 1 day after pKr-2 treatment. The density of p-4E-BP1, GDNF, and BDNF bands was normalized to the density of the β-actin band for each sample. *P<0.001 and ^**P<0.01 vs contralateral controls, pKr-2 alone and pKr-2 in the presence of GFP (one-way ANOVA and Tukey’s post hoc analysis; n=4, each experimental group). All values are expressed as the mean±s.e.m. (c) Western blot analysis of 4E-BP1, p-4E-BP1, GDNF, and BDNF in the SN at 7 days after pKr-2 treatment. The density of p-4E-BP1, GDNF, and BDNF bands was normalized to the density of the β-actin band for each sample. *P<0.001, ^**P<0.01 and ^***P<0.05 vs contralateral controls, ^##P<0.01 and ^###P<0.05 vs pKr-2 alone (one-way ANOVA and Tukey’s post hoc analysis; n=4, each experimental group). All values are expressed as the mean±s.e.m.